drugset

drugset / Trial / NCT00083707

Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia

NCT00083707 ↗

Phase 2 Completed 40 enrolled University of Arkansas Celgene Corporation · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this research is to study how helpful thalidomide is in controlling the disease and to study any side effects from taking thalidomide.

Timeline

Start: 1999-01
Primary completion: —
Completion: 2003-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Thalidomide	Other / unclassified	—	Oral

Indications